Continuing Education Activity
Latanoprost is an eye drop formulation helpful in the management of elevated intraocular pressure (IOP) within patients grappling with ocular hypertension or open-angle glaucoma. This prostaglandin F2 alpha analog is a frontline approach in glaucoma treatment, leveraging its proven efficacy in IOP reduction. Renowned for its convenience with a once-daily dosing regimen and an acceptable safety profile, prostaglandins like latanoprost have become the cornerstone of glaucoma therapy.
The United States Food and Drug Administration (FDA) approved the fixed-dose combination of netarsudil/latanoprost in March 2019, expanding treatment options for those afflicted with open-angle glaucoma and ocular hypertension. Beyond its approved applications, latanoprost is utilized off-label for diverse glaucoma variants. This activity covers latanoprost's mechanism of action, pharmacology, indications, adverse event profiles, contraindications, toxicity, and the collaborative efforts of the interprofessional team essential in managing conditions where latanoprost proves therapeutically beneficial.
Objectives:
Identify the appropriate indications for latanoprost in the treatment of glaucoma and ocular hypertension.
Screen patients for contraindications and potential drug interactions before initiating latanoprost therapy.
Assess patients' response to latanoprost therapy by regularly monitoring intraocular pressure and evaluating treatment effectiveness.
Develop effective communication with patients about latanoprost, explaining its benefits, potential side effects, and the importance of adherence.
Access free multiple choice questions on this topic.
Indications
FDA-Approved Indications
Latanoprost is an FDA-approved eye drop formulation to treat elevated intraocular pressure (IOP) in patients with ocular hypertension or open-angle glaucoma. The drug is a prostaglandin F2-alpha analog. Latanoprost reduces IOP by increasing the outflow of aqueous humor and improving the uveoscleral outflow.[1]
Prostaglandins are most commonly used as the first line of treatment in glaucoma due to their efficacy in reducing the IOP, convenience of once-daily dosing, and acceptable safety profile. Latanoprost is the first prostaglandin analog approved by the United States Food and Drug Administration (FDA). The drug was FDA-approved for ocular use in 1996.
Additionally, the fixed-dose combination (FDC) of netarsudil/latanoprost was approved by the USFDA in March 2019 for open-angle glaucoma (OAG) and ocular hypertension (OHT).[2]
Off-Label Uses
Latanoprost is used off-label for different variants of glaucoma.[3] These indications include:
Mechanism of Action
Prostaglandin synthesis occurs in the cell from arachidonic acid. Arachidonic acid, a 20-carbon molecule, gets metabolized to leukotrienes (LT) by lipoxygenases or converted to cyclic endoperoxides by cyclooxygenases. The cyclic endoperoxides are metabolized to prostaglandin F2-alpha (PGF2α) by prostaglandin synthase, reductase, and thromboxanes by thromboxane synthase.
Prostaglandin, thromboxane, and leukotriene are called eicosanoids. Various receptors exist for eicosanoids, including DP (prostaglandin D), EP (prostaglandin E), FP (prostaglandin F), IP (prostaglandin I or prostacyclin receptor), and TP (prostaglandin T). FP receptor has 2 variants: type A (full-length variant) and type B (spliced variant). Both FP receptors act as G-protein-coupled receptors. FP receptors are expressed in multiple ocular tissues, including ciliary smooth muscles.
Latanoprost is a PGF2α analog (FP receptor agonist) that increases the uveoscleral outflow of the aqueous fluid. Other PGF2α analogs with the same mechanism of action are travoprost and tafluprost.[4][5] The proposed mechanisms include:
Pharmacokinetics
Absorption: Latanoprost is absorbed through the cornea. The isopropyl ester of latanoprost gets hydrolyzed by the cornea to the acid, which is the biologically active form. Studies in men indicate that the peak concentration in the aqueous humor is reached about 2 hours after topical administration. The maximum drug concentration in the aqueous humor is achieved 2 hours after topical use of the drop. The drug starts reducing IOP after 3 to 4 hours of administration, and the maximum IOP-lowering effect is seen 8 to 12 hours after use. The IOP-lowering effect lasts for more than 24 hours, allowing once-daily dosage.
Distribution: The distribution volume in humans is 0.16 ± 0.02 L/kg. The solubility of latanoprost, travoprost, and unoprostone improves by adding isopropyl ester to the carboxyl-terminal of PGF2α. Adding a phenyl ring to the omega chain of PGF2α in the prostaglandin analogs (latanoprost, travoprost, bimatoprost) improves selectivity for the FP receptor. In animal studies, topical prostaglandin in high doses showed an initial IOP rise with a subsequent prolonged period (15 to 20 hours) of IOP reduction. A high dose may also disrupt the blood-aqueous barrier and cause conjunctival hyperemia. On the other hand, low-dose topical PG causes prolonged IOP reduction only.[6]
Metabolism: Latanoprost is an isopropyl ester prodrug. Esterases hydrolyze the prodrug in the cornea to the biologically active acid. The liver metabolizes the latanoprost reaching the systemic circulation to the 1,2-dinor and 1,2,3,4-tetranor by fatty acid β-oxidation.
Excretion: Latanoprost elimination from human plasma is rapid (t1/2 = 17 min) after intravenous and topical administration. Systemic clearance is 7 mL/min/kg. Following hepatic β-oxidation, the metabolites are mainly eliminated via the kidneys. Approximately 88% and 98% of the given dose are recovered in the urine after topical and IV dosing.
In animal studies, topical prostaglandin in high doses showed an initial IOP rise with a subsequent prolonged period (15 to 20 hours) of IOP reduction. A high dose may also disrupt the blood-aqueous barrier and cause conjunctival hyperemia. On the other hand, low-dose topical prostaglandin causes prolonged IOP reduction only.[6]
Administration
Available Dosage Forms and Strengths
Latanoprost is a colorless, isotonic ophthalmic solution available at a strength of 0.005%. According to the manufacturer, unopened bottles should be refrigerated at 2 °C to 8 °C (36 °F to 46 °F) for storage. During shipping, the container may remain at temperatures up to 40 °C (104 °F) for a period not exceeding 8 days. Upon opening the bottle, it may be stored at room temperature up to 25 °C (77 °F) for 6 weeks.
Adult Dosing
The dosage is 1 drop once daily at night, and the IOP lowering effect reduces (or paradoxical IOP rise may occur) when used more than once daily. The IOP lowering effect may be reduced due to subsensitivity at the FP receptors.[7]
Latanoprost may be administered with other antiglaucoma agents to reduce intraocular pressure. If more than 1 topical ophthalmic drug is being used, there should be a minimum gap of 5 minutes between each drop. Contact lenses should be removed before administering the medication, and the patient should not reinsert them within 15 minutes of the topical application of the drop. Latanoprost administration is topical, with 1 drop once daily in the evening in the affected eye(s).
The average IOP drop with latanoprost ranges from 30% to 35%. At 6 months, latanoprost was noted to reduce IOP by 35% when applied in the evening and 31% when instilled in the morning compared to timolol, which caused a 27% reduction in IOP.[8] A meta-analysis found that the mean IOP reduction (in mm Hg) with various antiglaucoma drugs was bimatoprost: 5.61, latanoprost: 4.85, travoprost: 4.83, levobunolol: 4.51, tafluprost: 4.37, timolol: 3.70, brimonidine: 3.59, carteolol: 3.44, levobetaxolol: 2.56, apraclonidine: 2.52, dorzolamide: 2.49, brinzolamide: 2.42, betaxolol: 2.24, and unoprostone: 1.91.[9]
Once-daily latanoprost has been shown to achieve a uniform round-the-clock reduction of IOP either alone or combined with a twice-daily dose of timolol.[10] The dosage is once daily using a combination drop of latanoprost and timolol.
Specific Patient Populations
Hepatic impairment: There is no information about dosage adjustments in patients with hepatic impairment in the manufacturer's labeling.
Renal impairment: There is no information about dosage adjustments in patients with renal impairment in the manufacturer's labeling.
Pregnancy considerations: This drug has been labeled FDA Category C. Prostaglandins stimulate uterine smooth muscle, inducing uterine contractions, and animal studies have indicated an augmented risk of abortion or preterm delivery. In animal reproduction studies, intravenous (IV) administration of latanoprost to pregnant rabbits and rats throughout organogenesis resulted in embryofetal lethality, malformations, and spontaneous abortion at clinically relevant doses. There are no adequate and well-controlled studies of latanoprost ophthalmic solution administration in pregnant women to advise regarding drug-associated risks. However, theoretically, prostaglandins increase uterine tone and can lead to premature labor. Hence, other classes of medications than latanoprost should be selected to treat glaucoma during pregnancy.[11][12]
Breastfeeding considerations: No information on using latanoprost during breastfeeding is available. Because of the drug's short half-life, it is not likely to reach the bloodstream of the infant or cause any adverse effects in breastfed infants. Professional guidelines consider prostaglandin eye drops acceptable during breastfeeding. To diminish the amount of drug that reaches the breastmilk after using eye drops, the clinician should advise the patient to place pressure over the tear duct by the corner of the eye for 1 minute or more, then remove the excess solution with an absorbent tissue.[13]
Adverse Effects
The primary adverse effects of latanoprost include eyelid edema, blurred vision, dry eyes, itching, redness, the growth of eyelashes, change in eyelid pigmentation (may become darker), iris, and eyelash. Other adverse effects of latanoprost include contact dermatitis/allergic conjunctivitis and an iris cyst.[14] See specific adverse effects listed below.
Conjunctival hyperemia: Conjunctival hyperemia is among the most common side effects noted in 5% to 15% of patients, more than in timolol-treated eyes. Latanoprost with a preservative (benzalkonium chloride) may reduce the goblet cell density.[15] The conjunctival redness usually appears within 2 to 3 days of initiation of the topical treatment, reduces within 1 month, and is typically mild with prolonged use.
Hypertrichosis: Hypertrichosis is an increase in the thickness, length, and number of eyelashes. Although this is preferred from a cosmetic point of view in some patients, the unilateral occurrence can be undesirable. The changes in the eyelashes are usually reversible after discontinuing the drug; this is due to the stimulation of the growth phase of the hair cycle.[1]
Pigmentation: The pigmentation is due to increased melanin in the melanocytes, but the number of melanocytes does not increase. There is an upregulation of the tyrosinase activity in the melanocytes.[16] The pigmentation may increase for the duration of drug use. The brownish color change of the iris after latanoprost use is permanent, but the pigmentation of the eyelid, periorbital tissue, and eyelash may be reversible. The pigmentation of the iris usually starts around the pupillary margin and then spreads towards the peripheral iris. Iris nevi and freckles are not affected by latanoprost. The pigmentation of the iris usually begins within 1 year of therapy and continues to increase with the use of the drug. Patients should receive counsel regarding the possible change in iris color, which may be more evident if using the medicine in only 1 eye. The iris pigmentation is more common in light-colored rides but may also occur in dark or brown rides. Darkening of the iris occurs in up to 10% of cases. Pigmentation of periocular tissue is reducible by removing the excess latanoprost drop from around the eye.[16]
Intraocular inflammation: Latanoprost may worsen intraocular inflammation (uveitis) and should be avoided in the actively inflamed eye.
Macular edema: Latanoprost may induce or aggravate macular edema, including cystoid macular edema. Patients with aphakia and pseudophakia with open posterior capsules are at higher risk of developing cystoid macular edema (CME).[17] Prostaglandin analogs (PGA) related to CME can be treated with discontinuation of the PGA. The most commonly used treatment strategy in pseudophakic CME is to suppress postsurgical inflammation using topical NSAIDs or corticosteroids, separately or combined. Corticosteroids are frequently used to treat pseudophakic CME because of their well-known anti-inflammatory effects.[17]
Reactivation of herpetic keratitis: This may occur with latanoprost, and patients with active herpetic keratitis should avoid latanoprost.[18] A contaminated multidose vial of latanoprost may cause bacterial keratitis in patients with a corneal epithelial defect or other corneal diseases.
Superficial punctate keratopathy: Damage to the ocular surface, including reduced tear break-up time, superficial punctate keratopathy may occur due to the preservative in latanoprost (benzalkonium), and the ocular surface toxicity has been noted to be less with preservative-free tafluprost.[19]
Contraindications
Latanoprost is contraindicated in patients with documented hypersensitivity to the drug or components of the formulation, including latanoprost (the active ingredient) or benzalkonium chloride (preservative), sodium chloride, monobasic sodium phosphate, and dibasic sodium phosphate.
Monitoring
Monitor for adverse drug reactions such as intraocular inflammation, pigmentary changes, and macular edema. Monitor intraocular pressure every 2 to 4 weeks until target intraocular pressure is attained. Subsequently, every 6 months is sufficient. For pediatric glaucoma, a 14-day home monitoring period provided a more than 90% chance of identifying an IOP spike.[20]
Toxicity
Researchers found no carcinogenesis or mutagenesis with latanoprost, and the drug did not affect fertility in animal studies. However, latanoprost was noted to cause a chromosomal aberration in treated human lymphocytes. Intravenous infusion of 3 μg/kg of latanoprost in healthy volunteers produced plasma concentrations 200 times higher than during clinical treatment with latanoprost ophthalmic solution, and researchers identified no ADR. There is no evidence to establish a correlation between latanoprost administration and ocular or cutaneous melanoma.[21]
Intravenous infusion of 5.5 to 10 μg/kg resulted in fatigue, sweating, dizziness, nausea, and abdominal pain. According to the manufacturer's labeling, treatment should be symptomatic if there is an overdosage with latanoprost ophthalmic solution.
Enhancing Healthcare Team Outcomes
Latanoprost is a prostaglandin analog considered for the first-line management of open-angle glaucoma. Multiple randomized control trials have proven its efficacy in lowering IOP in primary open-angle glaucoma, similar to travoprost and bimatoprost, but the latanoprost may demonstrate better tolerability.[22][1]
Retinal examination for cystoid macular edema and ruling out active inflammation before starting the therapy is vital. Also, the IOP should be monitored regularly by the ophthalmologist and the ophthalmic specialty-trained nurse to ensure the medication works. The pharmacist should educate the patient about the adverse effects of the drug, which may include darkening of the color of the iris, eyelids, periocular area, and eyelashes.[22]
An interprofessional team approach is needed to provide comprehensive and collaborative care for the patient. An ophthalmology-trained nurse and the pharmacist play a crucial role in assisting the prescriber in achieving this goal. The nurse can help educate the patient about the indication and expected outcomes of latanoprost therapy and the need for following up on IOP testing. The pharmacist can help the team by educating the patient about proper dosing, administration, storage, and adverse drug effects.
References
- 1.
Alm A. Latanoprost in the treatment of glaucoma.
Clin Ophthalmol. 2014;8:1967-85. [
PMC free article: PMC4196887] [
PubMed: 25328381]
- 2.
Radell JE, Serle JB. Netarsudil/latanoprost fixed-dose combination for the treatment of open-angle glaucoma or ocular hypertension.
Drugs Today (Barc). 2019 Sep;55(9):563-574. [
PubMed: 31584573]
- 3.
Digiuni M, Fogagnolo P, Rossetti L. A review of the use of latanoprost for glaucoma since its launch.
Expert Opin Pharmacother. 2012 Apr;13(5):723-45. [
PubMed: 22348427]
- 4.
Ocklind A. Effect of latanoprost on the extracellular matrix of the ciliary muscle. A study on cultured cells and tissue sections.
Exp Eye Res. 1998 Aug;67(2):179-91. [
PubMed: 9733584]
- 5.
Lindsey JD, Gaton DD, Sagara T, Polansky JR, Kaufman PL, Weinreb RN. Reduced TIGR/myocilin protein in the monkey ciliary muscle after topical prostaglandin F(2alpha) treatment.
Invest Ophthalmol Vis Sci. 2001 Jul;42(8):1781-6. [
PubMed: 11431442]
- 6.
Camras CB, Bito LZ, Eakins KE. Reduction of intraocular pressure by prostaglandins applied topically to the eyes of conscious rabbits.
Invest Ophthalmol Vis Sci. 1977 Dec;16(12):1125-34. [
PubMed: 924742]
- 7.
Lindén C, Alm A. Latanoprost twice daily is less effective than once daily: indication of receptor subsensitivity?
Curr Eye Res. 1998 Jun;17(6):567-72. [
PubMed: 9663846]
- 8.
Alm A, Stjernschantz J. Effects on intraocular pressure and side effects of 0.005% latanoprost applied once daily, evening or morning. A comparison with timolol. Scandinavian Latanoprost Study Group.
Ophthalmology. 1995 Dec;102(12):1743-52. [
PubMed: 9098273]
- 9.
Li T, Lindsley K, Rouse B, Hong H, Shi Q, Friedman DS, Wormald R, Dickersin K. Comparative Effectiveness of First-Line Medications for Primary Open-Angle Glaucoma: A Systematic Review and Network Meta-analysis.
Ophthalmology. 2016 Jan;123(1):129-40. [
PMC free article: PMC4695285] [
PubMed: 26526633]
- 10.
Rácz P, Ruzsonyi MR, Nagy ZT, Gaygi Z, Bito LZ. Around-the-clock intraocular pressure reduction with once-daily application of latanoprost by itself or in combination with timolol.
Arch Ophthalmol. 1996 Mar;114(3):268-73. [
PubMed: 8600885]
- 11.
Razeghinejad MR. Glaucoma medications in pregnancy.
Oman J Ophthalmol. 2018 Sep-Dec;11(3):195-199. [
PMC free article: PMC6219332] [
PubMed: 30505107]
- 12.
Belkin A, Chen T, DeOliveria AR, Johnson SM, Ramulu PY, Buys YM., American Glaucoma Society and the Canadian Glaucoma Society. A Practical Guide to the Pregnant and Breastfeeding Patient with Glaucoma.
Ophthalmol Glaucoma. 2020 Mar-Apr;3(2):79-89. [
PubMed: 32672600]
- 13.
Drugs and Lactation Database (LactMed®) [Internet]. National Institute of Child Health and Human Development; Bethesda (MD): Nov 15, 2024. Latanoprost. [
PubMed: 30000735]
- 14.
Lee JH, Kim TH, Kim SC. Allergic contact dermatitis caused by topical eye drops containing latanoprost.
Ann Dermatol. 2014 Apr;26(2):269-70. [
PMC free article: PMC4037689] [
PubMed: 24882991]
- 15.
Kahook MY, Noecker R. Quantitative analysis of conjunctival goblet cells after chronic application of topical drops.
Adv Ther. 2008 Aug;25(8):743-51. [
PubMed: 18670744]
- 16.
Grierson I, Jonsson M, Cracknell K. Latanoprost and pigmentation.
Jpn J Ophthalmol. 2004 Nov-Dec;48(6):602-12. [
PubMed: 15592791]
- 17.
Holló G, Aung T, Cantor LB, Aihara M. Cystoid macular edema related to cataract surgery and topical prostaglandin analogs: Mechanism, diagnosis, and management.
Surv Ophthalmol. 2020 Sep-Oct;65(5):496-512. [
PubMed: 32092363]
- 18.
Villegas VM, Díaz L, Izquierdo NJ. Herpetic keratitis in a patient who used two different prostaglandin analogue ophthalmic solutions: a case report.
P R Health Sci J. 2008 Dec;27(4):348-9. [
PubMed: 19069363]
- 19.
Tokuda N, Kitaoka Y, Matsuzawa A, Tsukamoto A, Sase K, Sakae S, Takagi H. Changes in Ocular Surface Characteristics after Switching from Benzalkonium Chloride-Preserved Latanoprost to Preservative-Free Tafluprost or Benzalkonium Chloride-Preserved Tafluprost.
J Ophthalmol. 2017;2017:3540749. [
PMC free article: PMC5558672] [
PubMed: 28831305]
- 20.
Bitner DP, Freedman SF. Long-term home monitoring of intraocular pressure in pediatric glaucoma.
J AAPOS. 2016 Dec;20(6):515-518. [
PubMed: 27702611]
- 21.
Tressler CS, Wiseman RL, Dombi TM, Jessen B, Huang K, Kwok KK, Wirostko BM. Lack of evidence for a link between latanoprost use and malignant melanoma: an analysis of safety databases and a review of the literature.
Br J Ophthalmol. 2011 Nov;95(11):1490-5. [
PubMed: 21515566]
- 22.
Parrish RK, Palmberg P, Sheu WP., XLT Study Group. A comparison of latanoprost, bimatoprost, and travoprost in patients with elevated intraocular pressure: a 12-week, randomized, masked-evaluator multicenter study.
Am J Ophthalmol. 2003 May;135(5):688-703. [
PubMed: 12719078]
Disclosure: Koushik Tripathy declares no relevant financial relationships with ineligible companies.
Disclosure: Preeti Patel declares no relevant financial relationships with ineligible companies.
Disclosure: Ragi Geetha declares no relevant financial relationships with ineligible companies.
